Abstract

The U.S. pharmaceutical sector stands as a foundation of national health and economic strength with revenue of over $550 billion a year, over 800 000 workers, and spending over $100 billion annually on research and development (R&D). A careful estimate of the scale of the industry is dependent on factors such as market size, estimates for capacity, an analysis of employment levels, revenue streams, and R&D spending using data collected by the U.S. Bureau of Economic Analysis (BEA), IQVIA, U.S. Bureau of Labor Statistics (BLS), as well as various company disclosures. The supply chain involving the network of manufacturing, distribution, regulation, logistics, cold chain, digital requirements, and resiliency are all major factors that will impact drug quality, cost, availability, patient safety, and other key performance indicators (KPIs) associated with an organization. The COVID-19 pandemic exposed fragility in global sourcing, reliance on single sourcing, and distribution-breaking bottlenecks in the pharmaceutical supply chain, prompting companies to pivot towards agile manufacturing processes, digital tracking, and regional resiliency hubs as encouraged by U.S. pharmaceutical companies such as Pfizer, Johnson & Johnson, and Merck. The purpose of this paper is to provide an overview on how to estimate scale in the pharmaceutical industry, identify impactful components of the supply chain, describing their impact on various outcomes, review case studies of major U.S. pharmaceutical companies, and discuss the implications of policy and strategy. Recommendations include enhancing data transparency, diversifying suppliers, investing in cold chain and digitalization, and working directly with regulators to ensure patient access and operational efficiency to the organization.